How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

998 results for

Androgenic Alopecia

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

81. A Study Evaluating the Efficacy and Safety of SM04554 Topical Solution in Male Subjects With Androgenetic Alopecia

of study medication Clinical diagnosis of alopecia areata or other non-AGA forms of alopecia Scalp hair loss on the treatment area, due to disease, injury, or medical therapy History of surgical correction (e.g., hair transplantation, scalp reduction) of hair loss on the scalp Previous exposure to SM04554 Use of any products (e.g., finasteride, minoxidil, platelet rich plasma, biotin) or devices (e.g., laser light therapy) purported to promote scalp hair growth within 24 weeks prior to the start (...) of the study Use of anti-androgenic therapies (e.g., spironolactone, flutamide, cyproterone acetate, cimetidine) within 12 weeks prior to the start of the study Use of medications that potentially cause drug-induced hair loss (e.g., depotestosterone, haloperidol, methotrexate, methylprednisolone, prednisone, testosterone, divalproex sodium) within 12 weeks prior to the start of the study Current use of an occlusive wig, hair extensions, or hair weaves History of hypersensitivity or allergies to any

2018 Clinical Trials

82. Systemic causes of hair loss. (Abstract)

Systemic causes of hair loss. Hair loss is both a common chief complaint by patients and a clinical challenge for physicians, especially general practitioners, yet few dermatological problems yield as much patient satisfaction when resolved as hair loss. The diagnosis is often attributed to androgen-related hair loss, while other causes, some of which are life-threatening but treatable, are overlooked. We searched for relevant literature on hair loss and supported these findings with our (...) clinical experience to identify seven major systemic etiologies of hair loss, ranging from infectious agents to consumption of unsafe supplements. Many causes are only described in the literature through case studies, though some original articles and meta-analyses are available. Careful history taking, proper examination techniques, and judicious use of laboratory tests are essential to reach at the correct diagnosis in a cost-effective manner when performing patient work-up. Such methodical

2016 Annals of Medicine

83. Characteristics of Men Who Report Persistent Sexual Symptoms after Finasteride Use for Hair Loss. Full Text available with Trip Pro

Characteristics of Men Who Report Persistent Sexual Symptoms after Finasteride Use for Hair Loss. Some men who use finasteride for hair loss report persistent sexual and other symptoms after discontinuing finasteride therapy.To determine whether these persistent symptoms after discontinuation of finasteride use are due to androgen deficiency, decreased peripheral androgen action, or persistent inhibition of steroid 5α-reductase (SRD5A) enzymes.Finasteride users, who reported persistent sexual (...) symptoms after discontinuing finasteride (group 1); age-matched finasteride users who did not report sexual symptoms (group 2); and healthy men who had never used finasteride (group 3).Sexual function, mood, affect, cognition, hormone levels, body composition, functional magnetic resonance imaging (fMRI) response to sexually and affectively valenced stimuli, nucleotide sequences of androgen receptor (AR), SRD5A1, and SRD5A2; expression levels of androgen-dependent genes in skin.Academic medical

2016 Journal of Clinical Endocrinology and Metabolism

84. In silicoprediction of prostaglandin D2 synthase inhibitors from herbal constituents for the treatment of hair loss. (Abstract)

In silicoprediction of prostaglandin D2 synthase inhibitors from herbal constituents for the treatment of hair loss. Many herbal topical formulations have been marketed worldwide to prevent hair loss or promote hair growth. Certain in vivo studies have shown promising results among them; however, the effectiveness of their bioactive constituents remains unknown.Recently, prostaglandin D2 (PGD2) inhibition has been discovered as a pharmacological mechanism for treating androgenic alopecia (AGA (...) pharmacokinetic properties and minimal adverse skin reactions. These compounds have the highest potential for further in vitro and in vivo investigation with the aim of developing safe and high-efficacy hair loss treatment.Copyright © 2015 Elsevier Ireland Ltd. All rights reserved.

2015 Journal of Ethnopharmacology

85. A novel finasteride 0.25% topical solution for androgenetic alopecia: pharmacokinetics and effects on plasma androgen levels in healthy male volunteers. (Abstract)

A novel finasteride 0.25% topical solution for androgenetic alopecia: pharmacokinetics and effects on plasma androgen levels in healthy male volunteers. Finasteride, a selective inhibitor of type 2 5-α reductase isoenzyme, inhibits the conversion of testosterone to dihydrotestosterone (DHT) and is indicated in the treatment of male androgenetic alopecia. The study objective was to evaluate a newly developed finasteride 0.25% topical solution in comparison to the marketed finasteride 1 mg tablet (...) , with respect to finasteride pharmacokinetics and suppressive effects on plasma DHT.24 healthy men with androgenetic alopecia were randomized in a single center, open-label, parallel-group, exploratory study, and received either multiple scalp applications of the topical solution b.i.d. or oral doses of the reference tablet o.d. for 7 days. Plasma finasteride, testosterone and DHT concentrations were determined.After multiple doses, mean (± SD) finasteride C(max) and AUC(0-t) corresponded to 0.46 ± 0.28 ng

2014 International journal of clinical pharmacology and therapeutics Controlled trial quality: uncertain

86. Prevalence of androgenic alopecia in patients with polycystic ovary syndrome and characterization of associated clinical and biochemical features. (Abstract)

Prevalence of androgenic alopecia in patients with polycystic ovary syndrome and characterization of associated clinical and biochemical features. To describe the prevalence of androgenic alopecia (AGA) in patients with polycystic ovary syndrome (PCOS) and to characterize associated clinical and biochemical features.Cross-sectional study.Multidisciplinary PCOS clinic at a tertiary academic center.A total of 254 women with PCOS according to the Rotterdam criteria were systematically examined (...) were more likely to report concern with hair loss (70.4% vs. 37.7%); however, their BDI-FS scores were no different from subjects without AGA. There were no differences between subjects with and without AGA in biochemical hyperandrogenism or metabolic parameters.AGA is prevalent in 22% of subjects meeting diagnostic criteria for PCOS. AGA is associated with other manifestations of clinical hyperandrogenism, but not with greater risk of biochemical hyperandrogenemia or metabolic dysfunction than

2014 Fertility and Sterility

87. "Cold" X5 HairlaserTM used to treat male androgenic alopecia and hair growth: an uncontrolled pilot study. Full Text available with Trip Pro

"Cold" X5 HairlaserTM used to treat male androgenic alopecia and hair growth: an uncontrolled pilot study. Various trials have been conducted on the management and treatment of androgenic alopecia (AGA) or male pattern hair loss using a variety of laser and light sources.For this feasibility study, the population was composed of males between the ages of 20 and 60 years who have been experiencing active hair loss within the last 12 months and the diagnosis of AGA. They also had a Norwood (...) X5 hairlaser device for treating male androgenic alopecia. From the repeated measures analysis of variance, difference in mean hair counts over time was statistically significant (F = 7.70; p-value < 0.0001). Subsequent, linear regression of mean hair counts at each time point was performed, and post-hoc analysis found an increasing trend of hair growth over time that was statistically significant (p-value < 0.0001) with the estimated slope of 1.406. Increased hair counts from the baseline

2014 BMC research notes Controlled trial quality: uncertain

88. An epidemiological study of androgenic alopecia in 3114 Korean patients. (Abstract)

An epidemiological study of androgenic alopecia in 3114 Korean patients. Androgenetic alopecia (AGA) is the most common type of hair loss, and is characterized by the transformation of terminal scalp hair into vellus hair. The epidemiology of AGA is not fully understood. A strong genetic basis has long been identified, although little is known of its nongenetic causes.To evaluate the association of AGA with a number of environmental factors, including smoking, drinking and sleeping habit.In (...) total, 3114 Korean individuals with AGA who attended any one of 17 dermatology clinics in 6 cities in South Korea between March 2011 and February 2012 were enrolled in the study. Epidemiologic a data were collected using a standard questionnaire.No association was seen between eating or sleeping habits and severity of hair loss. However, drinking and smoking were associated with the severity of AGA in male patients. We also found that patients of both genders with a family history had more advanced

2014 Clinical & Experimental Dermatology

89. Destruction of the arrector pili muscle and fat infiltration in androgenic alopecia. (Abstract)

Destruction of the arrector pili muscle and fat infiltration in androgenic alopecia. Androgenic alopecia (AGA) is the most common hair loss condition in men and women. Hair loss is caused by follicle miniaturization, which is largely irreversible beyond a certain degree of follicular regression. In contrast, hair loss in telogen effluvium (TE) is readily reversible. The arrector pili muscle (APM) connects the follicle to the surrounding skin.To compare histopathological features of the APM (...) in AGA and TE.Archival blocks of 4-mm scalp punch biopsies from eight patients with AGA and five with TE were obtained. New 4-mm biopsies from five normal cases were used as controls. Serial 7-μm sections were stained with a modified Masson's trichrome stain. 'Reconstruct' software was used to construct and evaluate three-dimensional images of the follicle and APM.The APM degenerated and was replaced by adipose tissue in all AGA specimens. Remnants of the APM remained attached to the hair follicle

2014 British Journal of Dermatology

90. Androgen deprivation therapy for prostate cancer and the risk of autoimmune diseases. (Abstract)

Androgen deprivation therapy for prostate cancer and the risk of autoimmune diseases. Androgen deprivation therapy (ADT) has been a mainstay of treatment for advanced prostate cancer (PCa), but limited studies have been performed to investigate the association between ADT and autoimmune diseases.We conducted a population-based nationwide cohort study of 17,168 patients newly diagnosed with PCa between 1996 and 2013 using the National Health Insurance Research Database (NHIRD) of Taiwan. Cox (...) , dermatomyositis, Hashimoto's thyroiditis, hypersensitivity vasculitis, Behcet's disease, polymyositis, alopecia areata, Wegener's granulomatosis, ulcerative colitis, autoimmune hemolytic anemia, pemphigus, multiple sclerosis, systemic sclerosis, Goodpasture syndrome, giant cell arteritis, thromboangitis obliterans, arteritis obliterans, and Kawasaki disease. The duration of ADT use as a time-dependent variable was also examined for its association with autoimmune diseases. We also performed six secondary

2019 Prostate cancer and prostatic diseases

91. Genome-wide gene expression dataset used to identify potential therapeutic targets in androgenetic alopecia Full Text available with Trip Pro

Genome-wide gene expression dataset used to identify potential therapeutic targets in androgenetic alopecia The microarray dataset attached to this report is related to the research article with the title: "A genomic approach to susceptibility and pathogenesis leads to identifying potential novel therapeutic targets in androgenetic alopecia" (Dey-Rao and Sinha, 2017) [1]. Male-pattern hair loss that is induced by androgens (testosterone) in genetically predisposed individuals is known (...) as androgenetic alopecia (AGA). The raw dataset is being made publicly available to enable critical and/or extended analyses. Our related research paper utilizes the attached raw dataset, for genome-wide gene-expression associated investigations. Combined with several in silico bioinformatics-based analyses we were able to delineate five strategic molecular elements as potential novel targets towards future AGA-therapy.

2017 Data in brief

92. Platelet-rich plasma—an ‘Elixir’ for treatment of alopecia: personal experience on 117 patients with review of literature Full Text available with Trip Pro

Platelet-rich plasma—an ‘Elixir’ for treatment of alopecia: personal experience on 117 patients with review of literature Platelet-rich plasma (PRP) has emerged as a new treatment modality in regenerative plastic surgery and dermatology. PRP is a simple, cost-effective and feasible treatment option with high patient satisfaction for hair loss and can be regarded as a valuable adjuvant treatment modality for androgenic alopecia and other types of non-scarring alopecias. Authors have (...) proposed a hair model termed "Golden anchorage with 'molecular locking' of ectodermal and mesenchymal components for survival and integrity of hair follicle (HF)" in this article. Golden anchorage comprises of bulge stem cells, ectodermal basement membrane and bulge portion of APM. PRP with its autologous supply of millions of growth factors works on 'Golden anchorage' along with keratinocytes (PDGF), dermal papilla (IGF and fibroblast growth factor), vasculature (VEGF and PDGF) and neural cells (Nerve

2017 Stem Cell Investigation

93. Role of Vitamin D in Androgenetic Alopecia

pattern,7 grades) and the Ludwig system for females which classify the Female Pattern Hair Loss into three grades depending on the reduction in hair density over the crown and frontal scalp with retention of the frontal hairline. Etiopathogenesis of Androgenetic Alopecia has not yet been fully elucidated. Genetic factors, hair follicle cycle abnormalities, aging process and androgen dependent process including end organ sensitivity have been all incriminated as etiological factors . Dermoscopy has (...) Hassan, Assiut University Study Details Study Description Go to Brief Summary: Androgenetic alopecia is a common form of diffuse hair loss in both men and women,It primarily affects the top and front of the scalp with different clinical presentations and there are numerous classification systems for grading purposes. Condition or disease Intervention/treatment Alopecia, Androgenetic Diagnostic Test: serum vitamin D level by ELISA Detailed Description: These systems vary from the simple systems based

2017 Clinical Trials

94. Therapeutic experience with oral finasteride for androgenetic alopecia in female-to-male transgender patients. (Abstract)

Therapeutic experience with oral finasteride for androgenetic alopecia in female-to-male transgender patients. Androgenic treatment of female-to-male transgender patients may result in androgenetic alopecia (AGA). Use of 5-alpha-reductase inhibitors are useful as oral treatment of AA in men. There are no previous studies of the use of finasteride in transgender men as treatment of AGA.To evaluate the effectiveness and safety of an oral 5α-reductase inhibitor (finasteride) for AA developed (...) in transgender men.This single-centre retrospective study enrolled female-to-male transgender patients with a clinical diagnosis of AGA to receive 1 mg of an oral type II 5α-reductase inhibitor for at least 12 months.In all, 10 patients were included in the study. All the patients received a clinical diagnosis of male-pattern AGA, with 90% classified as stage IV on the Norwood-Hamilton scale. Mean onset of AGA was 3.25 years after the introduction of androgenic treatment, and 70% of the patients had a family

2017 Clinical & Experimental Dermatology

95. Genome-wide differential expression profiling of long non-coding RNAs in androgenetic alopecia in a Chinese male population. (Abstract)

Genome-wide differential expression profiling of long non-coding RNAs in androgenetic alopecia in a Chinese male population. Androgenetic alopecia (AGA), or male pattern baldness (MPB), is the most common form of hair loss in males. A combination of genetic and androgen causes have been suggested as factors that contribute to the development of AGA. However, the specific molecular mechanisms that underly AGA remain largely unknown. Long non-coding RNAs (lncRNAs), a new class of regulatory non

2017 Journal of the European Academy of Dermatology and Venereology

96. Higher plasma leptin is associated with higher risk of androgenetic alopecia in men. Full Text available with Trip Pro

Higher plasma leptin is associated with higher risk of androgenetic alopecia in men. In addition to genetics and androgens, novel factors could play a role in androgenetic alopecia (AGA). This study aims to investigate the association between plasma leptin level with the risk and severity of AGA in men. Forty-eight subjects were enrolled including 29 AGA and 19 non-AGA subjects. The plasma leptin level was significantly higher in AGA subjects, compared to non-AGA subjects (4.45 vs 2.76 ng/mL, P

2017 Experimental Dermatology

97. Novel Approach to Treating Androgenetic Alopecia in Females With Photobiomodulation (Low-Level Laser Therapy). (Abstract)

sources operating at 650 nm and placed inside a sports cap to promote discretion while in use. The study demonstrates that low-level laser treatment of the scalp every other day for 17 weeks using the HANDI-DOME LASER device is a safe and effective treatment for androgenetic alopecia in healthy females between the ages of 18 to 60 with Fitzpatrick skin Types I to IV and Ludwig-Savin Baldness Scale I-2 to II-2 baldness patterns. Subjects receiving LLLT at 650 nm achieved a 51% increase in hair counts (...) Novel Approach to Treating Androgenetic Alopecia in Females With Photobiomodulation (Low-Level Laser Therapy). Photobiomodulation, also referred to as low-level laser therapy (LLLT), has been studied and used for (among other diseases) the promotion of hair regrowth.A clinical study was developed to define the physiologic effects that occur when the human hair follicle and surrounding tissue structures are exposed to laser light using a novel device that is fitted with an array of laser diode

2017 Dermatologic Surgery Controlled trial quality: uncertain

98. Adipocyte-myofibroblast transition as a possible pathophysiological step in androgenetic alopecia. Full Text available with Trip Pro

Adipocyte-myofibroblast transition as a possible pathophysiological step in androgenetic alopecia. Appearance of local fibrotic structures around and beneath hair follicles during their involution is a known hallmark of androgenetic alopecia (AGA). We hypothesise that this fibrosis can be connected with recently uncovered adipocyte-myofibroblast transition (AMT) involving the dermal adipocytes. This reflects that AMT is at least partially androgen-dependent, and we propose that AMT may play

2017 Experimental Dermatology

99. Male pattern baldness and the risk of prostate cancer. Full Text available with Trip Pro

. Statistical comparison was subsequently done between both groups of patients.Our study revealed that patients with prostate cancer were twice as likely to have androgenic alopecia at age 20 [odds ratio (OR) 2.01, P = 0.0285]. The pattern of hair loss was not a predictive factor for the development of cancer. There was no association between early-onset alopecia and an earlier diagnosis of prostate cancer or with the development of more aggressive tumors.This study shows an association between early-onset (...) Male pattern baldness and the risk of prostate cancer. Androgens play a role in the development of both androgenic alopecia, commonly known as male pattern baldness, and prostate cancer. We set out to study if early-onset androgenic alopecia was associated with an increased risk of prostate cancer later in life.A total of 669 subjects (388 with a history of prostate cancer and 281 without) were enrolled in this study. All subjects were asked to score their balding pattern at ages 20, 30 and 40

2011 Annals of Oncology

100. A Safety and Efficacy Study of Bimatoprost in Men With Androgenic Alopecia (AGA)

. For general information, Layout table for eligibility information Ages Eligible for Study: 18 Years to 49 Years (Adult) Sexes Eligible for Study: Male Accepts Healthy Volunteers: No Criteria Inclusion Criteria: Mild to moderate male pattern baldness (androgenic alopecia) with ongoing hair loss for at least 1 year Willingness to maintain same hair style, length and hair color during study Willingness to have micro-dot-tattoo applied to scalp (Stage 2 only) Exclusion Criteria: Drug or alcohol abuse within (...) Information provided by (Responsible Party): Allergan Study Details Study Description Go to Brief Summary: This is a safety and efficacy study of bimatoprost in male subjects with androgenic alopecia (AGA). Condition or disease Intervention/treatment Phase Alopecia Alopecia, Androgenetic Baldness Drug: Bimatoprost Solution 1 Drug: Bimatoprost Solution 2 Drug: Bimatoprost Vehicle Phase 2 Study Design Go to Layout table for study information Study Type : Interventional (Clinical Trial) Actual Enrollment

2013 Clinical Trials

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>